OBJECTIVE: A meta-analysis of randomized controlled trials (RCTs) was conducted to evaluate whether tranexamic acid (TXA) could significantly reduce blood loss during and after cesarean section (CS) when compared with no TXA. STUDY DESIGN: MEDLINE (PubMed), EMBASE, Cochrane Central Register of Controlled Trials and Web of Science were searched to identify RCTs that compared intravenous TXA with no TXA before CS for blood loss. The related data were extracted by two independent authors. The fixed or random-effect methods were used to combine data. RESULT: Eleven RCTs were included in this analysis with a total of 1276 women in TXA group and 1255 in no TXA (control) group. Total blood loss during and after CS was significantly less in TXA group than in control group (mean difference (MD) − 141.61 ml, 95% confidence interval (CI) − 207.09 to − 76.14, P o 0.01). There was a significant reduction in intraoperative and postpartum blood loss in TXA group as compared with control group (MD − 143.36 ml, 95% CI − 220.38 to − 66.35, P o 0.01; and MD − 38.20 ml, 95% CI − 59.27 to − 17.12, P o0.01, respectively). Declines in hemoglobin and hematocrit values after CS were both significantly less in TXA group than in control group. The difference of postpartum hemorrhage rate was statistically significant between groups (risk ratio (RR) 0.57, 95% CI 0.37 to 0.89, P = 0.01). The need for blood transfusion was significantly less in TXA group than control group (RR 0.23, 95% CI 0.10 to 0.57, P o0.01). CONCLUSION: Our results demonstrate that TXA offers an advantage over no TXA in reducing blood loss during and after CS.
INTRODUCTION
The rate of cesarean section (CS) has increased in both developed and developing countries in recent decades. 1 It was estimated in 2010 that CS rate was 32% in United States 2 and 42% in China, 3 which are both considerably higher than World Health Organization's recommended proportion of 10 to 15%. Delivery by CS is associated with more complications than vaginal delivery. One of the most common complications is postpartum hemorrhage (PPH) being regarded as the leading cause of preventable maternal mortality worldwide. 4 Besides, PPH is related with the increased rate of blood transfusion 5 and the occurrence of serious anemia. 6 Therefore, it is needed to explore effective approaches to reduce blood loss during and after CS.
Tranexamic acid (TXA), a synthetic derivative of the amino acid lysine, has been used in the treatment of bleeding for many years. It expressed its antifibrinolytic effect via the reversible blockade of the lysine binding sites on plasminogen molecules and the inhibition of plasminogen converting to plasmin. 7 Numerous studies have demonstrated that TXA had a vital role in preventing or decreasing intra-and postoperative blood loss in various surgeries including coronary artery bypass, arthroplasty, orthognathic surgery and liver transplantation. 8 In 2004, Gai et al. 9 first reported a multi-center, randomized controlled trial (RCT), showing a significant reduction in total blood loss and postpartum blood loss when TXA was administrated immediately before CS. To determine the clinical efficacy of TXA in decreasing bleeding during and after cesarean delivery, other obstetricians have continuously carried out the corresponding studies on different scales. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] However, the results have reached no consensus.
Therefore, we aimed to conduct a comprehensive meta-analysis of published RCTs to demonstrate the hypothesis that TXA could significantly reduce blood loss during and after CS when compared with no TXA.
METHODS
We performed this study in accordance with the Statement of Preferred Reporting Items for Systematic Reviews and Meta-Analyses. 20 
Search strategy
The electronic databases utilized in our literature search included MEDLINE (PubMed), EMBASE, Cochrane Central Register of Controlled Trials and Web of Science. The following MeSH terms and text words were used without language restrictions: 'tranexamic acid', 'antifibrinolyticagent', 'cesarean', 'caesarean', 'blood loss' and 'hemorrhage'. The latest search was conducted on 13 June 2015. Two authors independently reviewed the titles and abstracts identified in the search. All references cited in the articles were also searched by hand to identify additional publications.
Study selection
Only RCTs that compared intravenous TXA with no TXA before CS for intraoperative and postpartum blood loss were eligible for inclusion. If two or more trials from the same institution were identified, the most recent or the most informative was selected, unless they were reports from different time periods or if the data of overlapping patients could be subtracted. Retrospective studies, reviews and case reports were excluded. If it was impossible to calculate the quantity of blood loss from the published results then the assessed study was also excluded.
Data extraction
The data were extracted independently by the two reviews. Any discrepancies between the two authors were resolved by discussion or arbitration by a third author. The following information was extracted from each trial: first author's last name, publication year, country, study interval, patient characteristics (mean age, weight and gestational age), the doses of TXA, blood collection periods, blood loss measurement, the volumes of intraoperative and postpartum blood loss, the declines in hemoglobin and hematocrit values after CS, the incidence of PPH, blood loss 41000 ml, and blood transfusion.
Quality assessment
The methodological quality of the included RCTs was assessed and calculated using the Jadad scale, 21 which evaluates a study in terms of the description of randomization, double-blinding and withdrawals or dropouts. According to the scale, the studies were divided into a high-quality group (score ⩾ 3) and a low-quality group (score o3).
Statistical analysis
The outcomes were pooled as estimate of the overall effect for the metaanalysis conducted using the statistical software Review Manage, version 5.1.0 (The Cochrane Collaboration, 2011). Analysis of continuous variables was done by calculating the mean difference (MD) with the corresponding 95% confidence interval (CI) in inverse variance method. If studies reported continuous data as median and/or range values, s.d. was calculated using statistical algorithms by Hozo et al. 22 For dichotomous variables, the risk ratio (RR) for each study was aggregated in Mantel-Haenszel (M-H) method to obtain a pooled RR with a corresponding 95% CI. Assessment of statistical heterogeneity among studies was done by the Cochran's Q-test and I 2 statistics. For Q-test, P o0.1 was considered statistically significant. 23 As previously described, 24 if there was a significant heterogeneity, the random effects model would be used; otherwise, the fixed-effect model would be chosen. Funnel plot was constructed to detect the possibility of publication bias. 25 A symmetrical inverted funnel in the plot indicates the absence of this possibility, whereas an asymmetrical shape represents the presence of publication bias. The visual asymmetry of the funnel plot was tested by Egger's regression with Po0.1 considered as significant. 26 
RESULTS
Trial flow A total of 86 citations were identified from literature searches. After selection, 12 studies met the criteria for inclusion in the meta-analysis. Of these, one RCT by Shakur et al. 27 provided no outcome data for our analysis and was excluded. Therefore, 11 RCTs 9-19 were eligible for final inclusion with a total of 2531 women in our analysis. The flow diagram in Figure 1 details the selection process.
Study characteristics
The major study characteristics are summarized in Table 1 . All 11 trials were carried out in 6 countries and published in English-language journals between 2004 and 2013. A total of 1276 women in this analysis received intravenous administration of TXA and 1255 received nothing or placebo as control. Demographic factors in two groups were similar with no statistically significant difference. Eight studies [9] [10] [11] 13, 14, [16] [17] [18] applied TXA in the dose of 1g and two studies 12, 19 in the dose of 10 mg kg − 1 , whereas the study conducted by Goswami et al. 15 used two doses (10 mg kg − 1 and 15 mg kg − 1 ) of TXA in anemic parturients undergoing CS. The periods of blood collection and the measurement of blood loss in the included studies were presented in Table 2 . In total, no serious Gai et al. 9 From PD to the end of CS, and from the end of CS to 2-h postpartum ((Weight of used materials + unused materials − weight of all materials before CS)/1.05) + the volume included in the suction container after placental delivery Gohel et al. 10 From PD to the end of CS, and from the end of CS to 2-h postpartum (Weight of used materials in both the periods − weight of the materials before CS) + the volume included in the suction container after placental delivery; the pads used from the end of CS to 2-h postpartum were separately weighed Sekhavat et al. 11 From the end of CS to 2 h postpartum (Weight of used materials − weight of materials before used)/1.05; the soaked, specially designed operating sheet used from the end of CS to 2-h postpartum were separately weighed Gungorduk et al. 13 NA EBV × (preoperative hematocrit − 48-h postpartum hematocrit)/ preoperative hematocrit, where EBV in ml = the woman's weight in kg × 85 Movafegh et al. 12 From PD to the end of CS, and from the end of CS to 2-h postpartum ((Weight of bloody materials − weight of dry materials)/1.05) + the volume included in the suction container after placental delivery; the soaked pads and gauze used from the end of CS to 2-h postpartum were separately weighed Sentürk et al. 18 From the start of skin incision to before entrance of the intrauterine cavity, from uterine repair to closure of the skin, and during the patients in service room (Wet weight of materials − dry weight of materials)/1.05; the pad used in the service room was separately weighed Xu et al. 19 From PD to the end of CS, and from the end of CS to 2-h postpartum ((Weight of used materials + unused materials − weight of all materials before CS)/1.05) + the volume included in the suction container after placental delivery Shahid et al. 16 From PD to the end of CS, and from the end of CS adverse events associated with the use of TXA were recorded except two cases of deep vein thrombosis in each group reported by Xu et al. 19 Quality assessment With regard to methodological quality of included RCTs in this analysis, 10 trials 9-13,15-19 described in detail the method of randomization. Six trials 12, 13, [15] [16] [17] [18] [19] described as double-blind, whereas only two 12, 16 of them have appropriate double-blinding method. Withdrawals or dropouts were described in all trials. Sample size calculations were adequately described in five studies. 12, 13, 15, 17, 19 According to Jadad scoring system, all of the included RCTs were regarded as better quality trials except the trial by Halder et al. 14 (Table 1) .
Total blood loss
Nine included RCTs reported the volumes of total blood loss during and after CS. Of these, eight RCTs 9-13,16-19 showed a significant reduction in total blood loss when TXA was administrated intravenously, as compared with no TXA. One RCT by Halder et al., 14 however, found no significant difference in total bleeding between two groups. When nine RCTs were pooled in this analysis, the volume of total blood loss was significantly less in TXA group than control group by 141.61 ml (95% CI − 207.09 to − 76.14, P o 0.01; Figure 2 ). Subgroup analysis for the dose of 1g further showed a significant reduction in total blood loss in study group (MD − 141.81 ml, 95% CI − 224.34 to − 59.27, Po 0.01), whereas for the dose of 10 mg kg − 1 found that the reduction did not approach statistical significance (MD − 141.23 ml, 95% CI − 291.71 to 9.25, P = 0.07). Heterogeneities across studies were statistically significant (P o 0.1; Table 3 ).
Intraoperative blood loss
Information about intraoperative blood loss was described in seven trials. A significant difference of intraoperative bleeding between two groups was observed in five trials. 10, 12, [15] [16] [17] The other two trials 9, 19 reported that such difference was insignificant.
Our pooled results revealed that TXA could significantly reduce intraoperative blood loss when compared with control group (MD − 143.36 ml, 95% CI − 220.38 to − 66.35, P o 0.01; Figure 3 ). Besides, subgroup analyses for the doses of 1g (MD − 156.54 ml, 95% CI − 276.01 to − 37.08, P = 0.01), 10 mg kg − 1 (MD − 110.35 ml, 95% CI − 173.97 to − 46.73, P o 0.01), and 15 mg kg − 1 (MD − 266.00 ml, 95% CI − 303.68 to − 228.32, Po 0.01) all demonstrated the significant effect of TXA on decreasing intraoperative blood loss. Heterogeneities across studies were statistically significant (P o0.1; Table 3 ). A sensitivity analysis for the subgroup of dose of 10 mg kg − 1 was performed, and the result was unchanged (MD − 145.57 ml, 95% CI − 167.29 to − 123.86, P o0.01) with no heterogeneity across studies (I 2 = 0%, P = 0.72).
Postpartum blood loss
In our analysis, there were seven studies [9] [10] [11] [12] 16, 17, 19 providing the data of postpartum blood loss. These trials all exhibited a significant reduction in postpartum bleeding in study group except the trial by Shahid et al. 16 Our meta-analytic pooling showed a significant reduction of postpartum blood loss by 38.20 ml in TXA group (95% CI − 59.27 to − 17.12, P o 0.01; Figure 4 ). Subgroup analysis for the doses of 1 g (MD − 31.06 ml, 95% CI − 54.67 to − 7.45, P = 0.01) and 10 mg kg − 1 (MD − 57.00 ml, 95% CI − 92.03 to − 21.97, P o0.01) both revealed that this reduction was statistically significant. Statistical heterogeneities across studies were significant (P o 0.1; Table 3 ). 
Hemoglobin
Six trials 11, 12, 14, [17] [18] [19] reported the decline in hemoglobin values after CS. The pooling results of our meta-analysis (MD − 0.87 g dl − 1 , 95% CI − 1.30 to − 0.45, Po0.01; Figure 5 ) and subgroup analysis (doses of 1g (MD − 0.99 g dl − 1 , 95% CI − 1.65 to − 0.34, Po0.01) and 10 mg kg − 1 (MD − 0.64 g dl − 1 , 95% CI − 1.93 to − 0.34, Po0.01)) all showed that the decline in hemoglobin was significantly less in study group than in control group. Statistical heterogeneities across studies were significant (Po0.1; Table 3 ).
Hematocrit
Only two studies 11, 18 in this analysis provided the data regarding the decline in hematocrit level following CS. Both individual trials and meta-analysis suggested significantly less decline in hematocrit level in TXA group (MD − 1.82, 95% CI − 3.42 to − 0.23, P = 0.02; Figure 6 ). Statistical heterogeneities across studies were significant (P o0.1; Table 3 ).
Incidence of PPH Five trials 9, 10, 17, 19 reported the information of PPH rate. Four of these trials defined PPH as postpartum bleeding ⩾ 500 ml, whereas the trial by Gai et al. 9 used a value of 400 ml as threshold. Therefore, the data in the latter trial were not included in statistical analysis. Overall, 4.38% (25/571) parturients experienced PPH in study group and 8.07% (43/533) in control group. Our metaanalysis illustrated a significant difference of PPH rate between groups (RR 0.57, 95% CI 0.37 to 0.89, P = 0.01; Figure 7 ). No statistical heterogeneity across studies was found (I 2 = 0%, P = 0.47; Table 3 ). Incidence of excessive bleeding There were two trials 13, 17 in our analysis reported the incidence of blood loss 41000 ml. Overall, 1.28% (9/703) patients sustained such excessive bleeding in study group and 3.01% (21/697) in control group. Our meta-analysis showed that the difference of this outcome between groups was statistically significant (RR 0.43, 95% CI 0.20 to 0.92, P = 0.03; Figure 8 ) with no intergroup heterogeneity (I 2 = 0%, P = 0.37; Table 3 ).
Blood transfusion
Four trials 13, 15, 16, 18 provided the data about the need for blood transfusion. Overall, 0.95% (5/529) patients in study group needed blood transfusion comparing with 4.05% (21/518) patients in control group. A significant difference of blood transfusion between groups was observed in our meta-analysis (RR 0.23, 95% CI 0.10 to 0.57, P o 0.01; Figure 9 ). There was no heterogeneity across studies (I 2 = 0%, P = 0.84; Table 3 ).
Publication bias
Visual inspection of the funnel plot showed asymmetry ( Figure 10 ). Nevertheless, the Egger's regression analysis, conducted using STATA Version 12.0, demonstrated that the visual asymmetry was not significant (95% CI of intercept − 16.27 to 8.01, P = 0.45).
DISCUSSION
Our meta-analysis of 11 RCTs showed that TXA, given before the start of CS, could significantly decrease blood loss during and after CS with less hematological change when compared with no TXA. Moreover, our results found that TXA was associated with lower incidence of PPH and less need for blood transfusion. During placental separation, fibrinogen and fibrinare rapidly degraded, whereas plasminogen activators and fibrin degradation products increase due to activation of the fibrinolytic system, which can last 6 to 10-h postpartum, resulting in more bleeding. 28 In order to weaken the activity of the fibrinolytic system, TXA was chosen reasonably to reduce blood loss in obstetrical surgeries. In 2001, Yang et al. 29 employed 400 women with term singleton pregnancy, vertex presentation and spontaneous delivery to investigate the efficacy of TXA for preventing PPH. They have found that TXA in the dose of 1 g or 0.5 g could significantly reduce the postpartum blood loss as compared with no treatment. Later, a RCT 9 conducted in China recruited 180 primiparas to undergo CS, 91 of whom received 1 g of TXA intravenously. In that trial, a significant reduction in total blood loss from placental delivery to 2-h postpartum was observed in treatment group (352 vs 439 ml). However, a different study result has been reported from a trial 14 conducted in India, describing no significant difference of total blood loss between two groups (990 vs 1004 ml) with a lower Jadad score (2 points). Our meta-analysis, in accordance with the results of other recent trials, [16] [17] [18] [19] supported the notion of intravenous injection of TXA having a significant role in the reduction of total blood loss during and after CS.
Reducing operative blood loss would lower the risks and costs associated with blood transfusion. Blood is a scarce resource but even when blood is available, it can transmit potentially fatal viral infections. Although two trials 9, 19 conducted in China did not show any differences regarding intraoperative blood loss between the groups and explained as the time of TXA administration, our meta-analysis did demonstrate the superiority of intravenous TXA in decreasing blood loss during CS and the need for blood transfusion.
Many previous studies have found that the volume of postpartum bleeding could be effectively decreased by TXA in comparison to no TXA treatment. [9] [10] [11] [12] 16, 17, 19 Nevertheless, a trial 16 completed recently in Pakistan has not shown such satisfying outcome regarding postpartum bleeding with 36 ml in study group and 44 ml in control group (P40.05). Our findings in this analysis were in complete agreement with those studies supporting the advantage of TXA in reducing postpartum blood loss as compared with no TXA. Moreover, our results showed that the incidence of PPH was reduced significantly by intravenous TXA. In addition, the number of patients who sustained an excessive bleeding (41000 ml) was significantly less in our TXA group than in control group. These evidences raised the possibility that TXA may be an effective treatment for PPH, which accounts for about 166 000 maternal deaths every year, with an average interval from onset of bleeding to death of 2 to 4 h. 30 To demonstrate this hypothesis, Ducloy-Bouthors et al. 31 randomized 144 women with PPH 4800 ml following vaginal delivery to receive either TXA (n = 72) or not (n = 72). The study has found that blood loss from enrollment to 6 h later was significantly less by 48 ml in study group compared with control group. A larger scale trial, the WOMAN trial (World Maternal Antifibrinolytic Trial), aiming to enroll 15 000 women with PPH around the world, is currently being undertaken. 27 The trial will provide a stronger reliable evidence for the application of TXA in patients with PPH.
It was a concern that the volume of blood loss estimated during CS would be affected by amnion fluid. 32 Thus, in order to obtain more objective data, the declines of hemoglobin and hematocrit values after CS were noted and recorded in some trials. 11, 12, 14, [17] [18] [19] In accordance with the results of these studies, our meta-analysis showed a significantly less decline in hemoglobin and hematocrit levels in study group, which may be considered as a clinical effect of TXA on stabilizing the hematological change in the postpartum period.
It should be noted that our study involved three doses of TXA. Eight trials [9] [10] [11] 13, 14, [16] [17] [18] used TXA in dose of 1g, two 12, 19 in dose of 10 mg kg − 1 and one 15 in doses of 10 mg kg − 1 and 15 mg kg − 1 with a dose-dependent relationship demonstrated. Hence, we performed subgroup analyses and found that the results were similar to our meta-analyses although one exception presented (Table 3) . Given a much larger sample size, the potential difference of related outcome would be detected between the groups. Regrettably, we did not show the dose-dependent relationship of TXA due to the study design of each trial. Perhaps future studies focusing on this issue may provide more evidences to address this concern.
With regard to adverse effects of TXA therapy, most events are mild and transient. Although the incidence of thrombosis during pregnancy is 5 to 6 times higher than that in nonpregnant population, 33 thromboembolic events resulted from the use of TXA have been reported rarely. The included trial by Xu et al. 19 described that two women receiving TXA suffered from deep vein thrombosis, whereas another two women receiving no TXA experienced the same complication. None of the other included trials reported thromboembolic events or other serious side effects, which showed strong evidence for the safety of TXA in preventing or decreasing bleeding in pregnant woman. Despite these findings, it should be highly cautious to use TXA in women with history of thrombosis or other risk factors.
The main limitation of the present meta-analysis is the heterogeneity across studies. Clinical heterogeneity involves preparation and administration of the medication, surgical experience of the obstetricians, blood collection periods and calculation of the quantity of blood. For example, most trials measured blood loss from placental delivery to the end of CS and from the end of CS to 2-h postpartum, whereas two trials 17, 18 designed the period early to the skin incision and one 14 late to 2 days postpartum. The trial by Gungorduk et al. 13 used the difference of hematocrit values between before and 48 h after CS to estimate blood loss, which was different from the other trials using the difference of the weight of materials and the volume included in the suction container for calculation. The control group in this analysis involves placebo treatment and no treatment. Theoretically, these two designs should be analyzed separately. However, we could not do this due to the limited studies in this review. As a result, these potential variations might have influenced the results of this study. Assessment of statistical heterogeneity by the Q-test and I 2 statistics showed a significant heterogeneity among studies that could not be eliminated by sensitivity analysis except one outcome. Consequently, most pooled outcome measures were determined using a randomeffect model, which has taken those heterogeneities into account. Another limitation is potential publication bias on the basis of visual asymmetry of the funnel plot. The majority of included studies were conducted in Asia, which may introduce selection bias. This bias along with intergroup heterogeneity might have contributed to asymmetry in the funnel plot. However, our literature search was performed on several relevant databases according to the standards of the Cochrane Collaboration with no language restrictions. The study selection and data extraction were done independently by two authors. Moreover, the Egger's regression analysis provided no evidences for the presence of publication bias. Despite these, the results of our study need to be interpreted with caution.
CONCLUSION
In summary, our meta-analysis supports the use of TXA before CS for prevention of blood loss during and after CS compared with no TXA. It can safely decrease the incidence of PPH without increasing the risk of thrombosis. Given the significant intergroup heterogeneity in this study, further randomized, larger scale trials are needed to provide more evidences to demonstrate the efficacy of TXA in preventing blood loss during and after CS.
